Your browser doesn't support javascript.
Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations.
Efrati, Shai; Catalogna, Merav; Abu Hamad, Ramzia; Hadanny, Amir; Bar-Chaim, Adina; Benveniste-Levkovitz, Patricia; Levtzion-Korach, Osnat.
  • Efrati S; Research and Development Unit, Shamir Medical Center, Zerifin, Israel. efratishai@outlook.com.
  • Catalogna M; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. efratishai@outlook.com.
  • Abu Hamad R; Research and Development Unit, Shamir Medical Center, Zerifin, Israel.
  • Hadanny A; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Bar-Chaim A; Clinical Chemistry Laboratory, Shamir Medical Center, Zerifin, Israel.
  • Benveniste-Levkovitz P; Research and Development Unit, Shamir Medical Center, Zerifin, Israel.
  • Levtzion-Korach O; Clinical Chemistry Laboratory, Shamir Medical Center, Zerifin, Israel.
Sci Rep ; 11(1): 16543, 2021 08 16.
Article in English | MEDLINE | ID: covidwho-1360208
ABSTRACT
Since COVID-19 risk of reinfection is of great concern, the safety and efficacy of the mRNA-based vaccines in previously infected populations should be assessed. We studied 78 individuals previously infected with SARS-CoV-19, who received a single dose of BNT162b2 mRNA COVID-19 vaccine, and 12 ratio matched infection-naïve cohort who received two injections. The evaluation procedure included symptom monitoring, and serological tests. Among the post-infected population, the median IgG-S response after the first vaccine dose was 3.35 AU, compared to 2.38 AU after the second vaccine injection in the infection naive group. A strong correlation was demonstrated between IgG-S level before vaccination, and the corresponding responses after a single vaccine dose (r = 0.8, p < 0.001) in the post infected population. Short-term severe symptoms that required medical attention were found in 6.8% among the post-infected individuals, while none were found in the infection naïve population. Our data suggest that a single vaccine dose is sufficient to induce an intense immune response in post-infected population regardless of seropositivity. Although some short-term safety issues were observed compared to the infection naïve population, a single dose regimen can be considered safe in post-infected populations.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccination / Reinfection / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-96129-6

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccination / Reinfection / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-96129-6